Rosiglitazone attenuates hypoxia-induced pulmonary arterial remodeling

American Journal of Physiology - Lung Cellular and Molecular Physiology

Volumn 292, Issue 4, 2007, Pages

  Crossno Jr , Joseph T ^a,b   Garat, Chrystelle V ^c   Reusch, Jane E B ^a,c   Morris, Kenneth G ^b   Dempsey, Edward C ^a,b   McMurtry, Ivan F ^b   Stenmark, Kurt R ^b   Klemm, Dwight J ^a,b  

^a VETERANS AFFAIRS MEDICAL CENTER   (United States)

^b UNIVERSITY OF COLORADO   (United States)

^c UNIVERSITY OF COLORADO SCHOOL OF MEDICINE   (United States)

Author keywords

Metalloproteinase; Peroxisome proliferator activated receptor; Pulmonary hypertension; Right ventricular hypertrophy; Thiazolidinedione

Indexed keywords

COLLAGEN; ELASTIN; FASUDIL; METALLOPROTEINASE; MONOCROTALINE; ROSIGLITAZONE; STEM CELL FACTOR;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; ATHEROSCLEROSIS; BLOOD PRESSURE REGULATION; CELL PROLIFERATION; CONTROLLED STUDY; DRUG EFFECT; ENZYME ACTIVITY; FEMALE; HYPOXIA; MALE; NONHUMAN; PRIORITY JOURNAL; PULMONARY ARTERY; PULMONARY HYPERTENSION; RAT; SMOOTH MUSCLE FIBER; VASCULARIZATION;

ANIMALS; ANOXIA; BLOOD PRESSURE; COLLAGEN; ELASTIN; EXTRACELLULAR MATRIX; FEMALE; HYPERTENSION, PULMONARY; HYPERTROPHY, RIGHT VENTRICULAR; MALE; PPAR GAMMA; PROTO-ONCOGENE PROTEINS C-KIT; PULMONARY ARTERY; RATS; RATS, INBRED WKY; THIAZOLIDINEDIONES;

EID: 34247282656     PISSN: 10400605     EISSN: 15221504     Source Type: Journal    
DOI: 10.1152/ajplung.00258.2006     Document Type: Article

References (65)

1. Asakawa M, Takano H, Nagai T, Uozumi H, Hasegawa H, Kubota N, Saito T, Masuda Y, Kadowaki T, Komuro I. Peroxisome proliferator-activated receptor γ plays a critical role in inhibition of cardiac hypertrophy in vitro and in vivo. Circulation 105: 1240-1246, 2002.
2. Bell D, McDermott BJ. Effects of rosiglitazone and interactions with growth-regulating factors in ventricular cell hypertrophy. Eur J Pharmacol 508: 69-76, 2005.
3. Benson S, Padmanabhan S, Kurtz KW, Pershadsingh HA. Ligands for the peroxisome proliferator-activated receptor-γ and the retinoid X receptor-α exert synergistic antiproliferative effects on human coronary artery smooth muscle cells. Mol Cell Biol Res Commun 3: 159-164, 2000.
4. Benson S, Wu J, Padmanabhan S, Kurtz TW, Pershadsingh HA. Peroxisome proliferator-activated receptor (PPAR)-γ expression in human vascular smooth muscle cells: inhibition of growth, migration, and c-fos expression by the peroxisome proliferator-activated receptor (PPAR)-γ activator troglitazone. Am J Hypertens 13: 74-82, 2000.
5. Bentley J, Rickaby D, Haworth ST, Hanger CC, Dawson CA. Pulmonary arterial dilation by inhaled NO: arterial diameter, NO concentration relationship. J Appl Physiol 91: 1948-1954, 2001.
6. Bizzarro M, Gross I. Inhaled nitric oxide for the postoperative management of pulmonary hypertension in infants and children with congenital heart disease. Cochrane Database Syst Rev 4: CD005055, 2005.
7. Buchanan TA, Meehan WP, Jeng YY, Yang DC, Chan TM, Nadler JL, Scott S, Rude RK, Hsueh WA. Blood pressure lowering by pioglitazone: evidence for a direct vascular effect. J Clin Invest 96: 354-360, 1995.
8. Chen C, Schultz GS, Bloch M, Edwards PD, Tebes S, Mast BA. Molecular and mechanistic validation of delayed healing rat wounds as a model for human chronic wounds. Wound Repair Regen 7: 486-494, 1999.
9. Chen Z, Ishibashi S, Perrey S, Osuga J, Gotoda T, Kitamine T, Tamura Y, Okazaki H, Yahagi N, Iizuka Y, Shionoiri F, Ohashi K, Harada K, Shimano H, Nagai R, Yamada N. Troglitazone inhibits atherosclerosis in apolipoprotein E knockout mice: pleiotropic effects in CD36 expression and HDL. Arterioscler Thromb Vasc Biol 21: 372-377, 2001.
10. Clozel JP, Saunier C, Hartemann D, Fischli W. Effects of cilazapril, a novel angiotensin converting enzyme inhibitor, on the structure of pulmonary arteries exposed to chronic hypoxia. J Cardiovasc Pharmacol 17: 36-40, 1991.
11. Collins AR, Meehan WP, Kintscher U, Jackson S, Wakino S, Noh G, Palinski W, Hsueh WA, Law RE. Troglitazone inhibits formation of early atherosclerotic lesions in diabetic and nondiabetic low density lipoprotein receptor-deficient mice. Arterioscler Thromb Vasc Biol 21: 365-371, 2001.
12. Davie NJ, Crossno J, JT, Frid MG, Hofmeister SE, Reeves JT, Hyde DM, Carpenter TC, Brunetti JA, McNeice IK, Stenmark KR. Hypoxia-induced pulmonary artery adventitial remodeling and neovascularization: contribution of progenitor cells. Am J Physiol Lung Cell Mol Physiol 286: L668-L678, 2004.
13. Delerive P, Martin-Nizard F, Chinetti G, Trottein F, Fruchart JC, Najib J, Duriez P, Steals B. Peroxisome proliferator activated receptor activators inhibit thrombin-induced endothelin-1 production in human vascular endothelial cells by inhibiting the activator protein-1 signaling pathway. Circ Res 85: 394-402, 1998.
14. Desvergne B, Ijpenberg A, Devchand P, Wahli W. The peroxisome proliferator-associated receptors at the cross-road of diet and hormonal signaling. J Steroid Biochem Mol Biol 65: 65-74, 1998.
15. Dong FQ, Li H, Cai WM, Tao J, Ruan Y, Zheng FP, Zhang Z. Effects of pioglitazone on expression of matrix metalloproteinases 2 and 9 in kidneys of diabetic rats. Chin Med J (Engl) 117: 1040-1044, 2004.
16. Dorn GW, Force T. Protein kinase cascades in the regulation of cardiac hypertrophy. J Clin Invest 115: 527-537, 2005.
17. Duan SZ, Ivashchenko CY, Russell MW, Milstone DS, Mortensen RM. Cardiomyocyte-specific knockout and agonist of peroxisome proliferator-activated receptor-γ both induce cardiac hypertrophy in mice. Circ Res 97: 372-379, 2005.
18. Dubey RK, Zhang HY, Reddy SR, Boegehold MA, Kotchen TA. Pioglitazone attenuates hypertension and inhibits growth of renal arteriolar smooth muscle in rats. Am J Physiol Regul Integr Comp Physiol 265: R726-R732, 1993.
19. Durmowicz AG, Orton EC, Stenmark KR. Progressive loss of vasodilator responsive component of pulmonary hypertension in neonatal calves exposed to 4,570 m. Am J Physiol Heart Circ Physiol 265: H2175-H2183, 1993.
20. Fagan KA, Oka M, Bauer NR, Gebb SA, Ivy DD, Morris KG, McMurtry IF. Attenuation of acute hypoxic pulmonary vasoconstriction and hypoxic pulmonary hypertension in mice by inhibitors of Rho kinase. Am J Physiol Lung Cell Mol Physiol 287: L656-L664, 2004.
21. Frid MG, Brunetti JA, Burke DL, Carpenter TC, Davie NJ, Reeves JT, Roedersheimer MT, van Rooijen N, Stenmark KR. Hypoxia-induced pulmonary vascular remodeling requires recruitment of circulating mesenchymal precursors of a monocyte/macrophage lineage. Am J Pathol 168: 659-669, 2006.
22. Fukuda N, Hu WY, Teng J, Chikara S, Nakayama M, Kishioka H, Kanmatsuse K. Troglitazone inhibits growth and improves insulin signaling by suppression of angiotensin II action in vascular smooth muscle cells from spontaneously hypertensive rats. Atherosclerosis 163: 229-239, 2002.
23. Fukunaga Y, Itoh H, Doi K, Tanaka T, Yamashita J, Chun TH, Inoue M, Masatsugu K, Sawada N, Saito T, Hosoda K, Kook H, Ueda M, Nakao K. Thiazolidinediones, peroxisome proliferator activated receptor gamma activators, regulate endothelial cell growth and secretion of vasoactive peptides. Atherosclerosis 158: 113-119, 2001.
24. Garat CV, Fankell D, Erickson PF, Reusch JEB, Bauer NN, McMurtry IF, Klemm DJ. Platelet-derived growth factor BB induces nuclear export and proteasomal degradation of CREB via phosphatidylinositol 3-kinase/Akt signaling in pulmonary artery smooth muscle cells. Mol Cell Biol 26: 4934-4948, 2006.
25. Garg R, Kumbkarni Y, Aljada A, Mohanty P, Ghanim H, Hamouda W, Dandona P. Troglitazone reduces reactive oxygen species generation by leukocytes and lipid peroxidation and improves flow-mediated vasodilatation inn obese subjects. Hypertension 36: 430-435, 2000.
26. Goetze S, Kim S, Xi XP, Graf K, Yang DC, Fleck E, Meehan WP, Hsueh WA, Law RE. Troglitazone inhibits mitogenic signaling by insulin in vascular smooth muscle cells. J Cardiovasc Pharmacol 35: 749-757, 2000.
27. Goetze S, Kintscher U, Kim S, Meehan WP, Kaneshiro K, Collins AR, Fleck E, Hsueh WA, Law RE. Peroxisome proliferator-activated receptor-gamma ligands inhibit nuclear but not cytosolic extracellular signal-regulated kinase/mitogen-activated protein kinase-regulated steps in vascular smooth muscle migration. J Cardiovasc Pharmacol 38: 909-921, 2001.
28. Goetze S, Xi XP, Kawano H, Gotlibowski T, Fleck E, Hsueh WA, Law RE. PPARγ-ligands inhibit migration mediated by multiple chemoattractants in vascular smooth muscle cells. J Cardiovasc Pharmacol 33: 798-806, 1999.
29. Hataishi R, Zapol WM, Bloch KD, Ichinose F. Inhaled nitric oxide does not reduce systemic vascular resistance in mice. Am J Physiol Heart Circ Physiol 290: H1826-H1829, 2006.
30. Hattori Y, Akimoto K, Kasai K. The effects of thiazolidinediones on vascular smooth muscle cell activation by angiotensin II. Biochem Biophys Res Commun 273: 1144-1149, 2000.
31. Hayashida K, Fujita J, Miyake Y, Kawada H, Ando K, Ogawa S, Fukuda K. Bone marrow-derived cells contribute to pulmonary vascular remodeling in hypoxia-induced pulmonary hypertension. Chest 127: 1793-1798, 2005.
32. Horio T, Suzuki M, Suzuki K, Takimasawa I, Hiuge A, Kamide K, Takiuchi S, Iwashima Y, Kihara S, Funahashi T, Yoshimasa Y, Kawano H. Pioglitazone improves left ventricular diastolic function in patients with essential hypertension. Am J Hypertens 18: 949-957, 2005.
33. Howell K, Preston RJ, McLoughlin P. Chronic hypoxia causes angiogenesis in addition to remodeling in the adult rat pulmonary circulation. J Physiol 547: 133-145, 2003.
34. Hsueh WA, Law RE. PPARγ and atherosclerosis: effects on cell growth and movement. Arterioscler Thromb Vasc Biol 21: 1891-1895, 2001.
35. Hyvelin JM, Howell K, Nichol A, Cosello CM, Preson RJ, McLoughlin P. Inhibition of Rho kinase attenuates hypoxia-induced angiogenesis in the pulmonary circulation. Circ Res 97: 185-191, 2005.
36. Isseman I, Green S. Activation of a member of the steroid hormone receptor superfamily by the peroxisome proliferators. Nature 347: 645-650, 1990.
37. Jackson SM, Parhami F, Xi XP, Berliner JA, Hsueh WA, Law RE, Demer LL. Peroxisome proliferator-activated receptor activators target human endothelial cells to inhibit leukocyte-endothelial cell interaction. Arterioscler Thromb Vasc Biol 19: 2094-2104, 1999.
38. Jawien A, Bowen-Pope DF, Linder V, Schwartz SM, Clowes AW. Platelet-derived growth factor promotes smooth muscle migration and intimal thickening in a rat model of balloon angioplasty. J Clin Invest 89: 507-511, 1992.
39. Klemm DJ, Watson P, Frid MG, Dempsey EC, Schaack J, Colton LA, Nesterova A, Stenmark KR, Reusch JEB. cAMP response element-binding protein content is a molecular determinant of smooth muscle cell proliferation and migration. J Biol Chem 276: 46132-46141, 2001.
40. Koshiyama H, Shimono D, Kuwamura N, Minamikawa J, Nakamura Y. Rapid communication: inhibitory effect of pioglitazone on carotid arterial wall thickness in type 2 diabetes. J Clin Endocrinol Metab 86: 3452-3456, 2001.
41. Langenfeld MR, Forst T, Hohberg C, Kann P, Lubben G, Konrad T, Fullert SD, Sachara C, Pfutzner A. Pioglitazone decreases carotid intimal-media thickness independently of glycemic control in patients with type 2 diabetes mellitus: results from a controlled randomized study. Circulation 111: 2525-2531, 2005.
42. Law RE, Meehan WP, Xi XP, Graf K, Wuthrich DA, Coats W, Faxon D, Hsueh WA. Troglitazone inhibits vascular smooth muscle cell growth and intimal hyperplasia. J Clin Invest 98: 1897-1905, 1996.
43. Marx N, Bourcier T, Sukhova GK, Libby P, Plutsky J. PPARγ activation of human endothelial cells increases plasminogen activator inhibitor type-1 expression: PPARγ as a potential mediator in vascular disease. Arterioscler Thromb Vasc Biol 19: 546-551, 1999.
44. Marx N, Schonbeck U, Lazar MA, Libby P, Plutsky J. Peroxisome proliferator-activated receptor γ activators inhibit gene expression and migration in human vascular smooth muscle cells. Circ Res 83: 1097-1103, 1998.
45. Matsuda Y, Hoshikawa Y, Ameshima S, Suzuki S, Okada Y, Tabata T, Sugawara T, Matsumura Y, Kondo T. Effects of peroxisome proliferator- activated receptor γ ligands on monocrotaline-induced pulmonary hypertension in rats [in Japanese]. Nihon Kokyuki Gakkai Zasshi 43: 283-288, 2005.
46. 1 arrest and differentiation marker expression in vascular smooth muscle cells. Mol Pharmacol 58: 837-844, 2000.
47. Morisette MR, Cook SA, Foo S, McKoy G, Ashida N, Novikov M, Scherrer-Crosbie M, Li L, Matsui T, Brooks G, Rosenzweig A. Myostatin regulates cardiomyocyte growth through modulation of Akt signaling. Circ Res 99: 15-24, 2006.
48. Nagaoka T, Fagan KA, Gebb SA, Morris KG, Suzuki T, Shimokawa H, McMurtry IF, Oka M. Inhaled Rho kinase inhibitors are potent and selective vasodilators in rat pulmonary hypertension. Am J Respir Crit Care Med 171: 494-499, 2005.
49. Nemoto S, Razeghi P, Ishiyama M, De Freitas G, Taegtmeyer H, Carabello BA. PPAR-γ agonist rosiglitazone ameliorates ventricular dysfunction in experimental chronic mitral regurgitation. Am J Physiol Heart Circ Physiol 288: H77-H82, 2005.
50. Oka M, Morris KG, McMurtry IF. NIP-121 is more effective than nifedipine in acutely reversing chronic pulmonary hypertension. J Appl Physiol 75: 1075-1080, 1993.
51. Ono Y, Ito H, Tamamori M, Nozato T, Adachi S, Abe S, Marumo F, Hiroe M. Role and relation of p70 S6 and extracellular signal-regulated kinases in the phenotypic changes of hypertrophy of cardiac myocytes. Jpn Circ J 64:695-700, 2000.
52. Pershadsingh HA, Szollosi J, Benson SC, Kurtz TW. Pharmacological reversal of hyperinsulinemia is associated with a reduction in blood pressure: a novel approach to the treatment of hypertension. Hypertension 20: 322-324, 1992.
53. Pfutzner A, Marx N, Lubben G, Langenfeld MR, Walcher D, Konrad T, Forst T. improvement of cardiovascular risk markers by pioglitazone is independent from glycemic control: results from the pioneer study. J Am Coll Cardiol 45: 1925-1931, 2005.
54. Pietra GG, Capron F, Stewart S, Leone O, Humbert M, Robbins IM, Reid LM, Tuder RM. Pathologic assessment of vasculopathies in pulmonary hypertension. J Am Coll Cardiol 43: 25S-32S, 2004.
55. Rabinovitch M. Pathobiology of pulmonary hypertension. Extracellular matrix. Clin Chest Med 22: 433-449, 2001.
56. Rubin LJ. Cellular and molecular mechanisms responsible for the pathogenesis of primary pulmonary hypertension. Pediatr Pulmonol Suppl 18: 194-197, 1999.
57. Spiegelman BM, Flier JS. Adipogenesis and obesity: rounding out the big picture. Cell 87: 377-389, 1996.
58. Steals B, Koenig W, Habib A, Merval R, Lebret M, Torra IP, Delerive P, Fadel A, Chinetti G, Fruchart JC, Najib J, Maclouf J, Tedgui A. Activation of human aortic smooth muscle cells is inhibited by PPARα but not PPARγ activators. Nature 393: 790-793, 1998.
59. Stenmark KR, McMurtry IF. Vascular remodeling versus vasoconstriction in chronic hypoxic pulmonary hypertension: a time for reappraisal. Circ Res 97: 95-98, 2005.
60. Takeda K, Ichiki T, Tokunou T, Funakoshi Y, Iino N, Hirano K, Kanaide H, Takeshita A. Peroxisome-activated receptor γ activators downregulate angiotensin II type 1 receptor in vascular smooth muscle cells. Circulation 102: 1834-1839, 2000.
61. 2 and thiazolidinediones activate the MEK/ERK pathway through phosphatidylinositol 3-kinase in vascular smooth muscle cells. J Biol Chem 276: 48950-48955, 2001.
62. Wakino S, Hayashi K, Kanda T, Tatematsu S, Homma K, Yoshioka K, Takamatsu I, Saruta T. Peroxisome proliferator-activated receptor γ ligands inhibit Rho/Rho kinase pathway by inducing protein tyrosine phosphatase SHP-2. Circ Res 95: e45-e55, 2004.
63. Cip1 by modulating the protein kinase Cδ pathway in vascular smooth muscle cells. J Biol Chem 276: 47650-47657, 2001.
64. Yamamoto K, Ohki R, Lee RT, Ikeda U, Shimada K. Peroxisome proliferator-activated receptor γ activators inhibit cardiac hypertrophy in cardiac myocytes. Circulation 104: 1670-1675, 2001.
65. Zafiriou S, Stanners SR, Saad S, Polhill TS, Poronnik P, Pollock CA. Pioglitazone inhibits cell growth and reduces matrix production in human kidney fibroblasts. J Am Soc Nephrol 16: 638-645, 2005.